Literature DB >> 2447163

Inhibitory activity of interferons and interleukin 1 on the development of Plasmodium falciparum in human hepatocyte cultures.

S Mellouk1, R K Maheshwari, A Rhodes-Feuillette, R L Beaudoin, N Berbiguier, H Matile, F Miltgen, I Landau, S Pied, J P Chigot.   

Abstract

We have studied the effect of natural and recombinant human interferons (HuIFN-alpha, -beta, and -gamma), and interleukin 1 (IL-1) on development of sporozoites of Plasmodium falciparum in cultures of functional hepatocytes. HuIFN-gamma inhibits hepatic schizogony of P. falciparum at very low concentrations (0.1 to 10 international units/ml), the target being the hepatocyte. Application after sporozoite inoculation is effective, suggesting an intracellular mechanism. There is also an 84% inhibition after application from 4 to 6 days following inoculation so that by day 6, there was a disappearance of a significant number of schizonts previously present at day 4, indicating more than a parasitostatic effect, and probably a postassembly action. HuIFN-alpha and -beta were effective, but only at 1000-fold higher concentrations than HuIFN-gamma. IL-1 (5 U/ml) also inhibited hepatic development of P. falciparum sporozoites; however, IL-1 treatment was effective only when applied before sporozoite inoculation.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2447163

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  43 in total

1.  Immunogenicity of well-characterized synthetic Plasmodium falciparum multiple antigen peptide conjugates.

Authors:  M B Joshi; A A Gam; R A Boykins; S Kumar; J Sacci; S L Hoffman; H L Nakhasi; R T Kenney
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

Review 2.  Parasite heat-shock proteins and host responses: the balance between protection and immunopathology.

Authors:  D Mazier; D Mattei
Journal:  Springer Semin Immunopathol       Date:  1991

3.  Serum cytokine profiles in experimental human malaria. Relationship to protection and disease course after challenge.

Authors:  R Harpaz; R Edelman; S S Wasserman; M M Levine; J R Davis; M B Sztein
Journal:  J Clin Invest       Date:  1992-08       Impact factor: 14.808

4.  Antibody-mediated and cellular immune responses induced in naive volunteers by vaccination with long synthetic peptides derived from the Plasmodium vivax circumsporozoite protein.

Authors:  Myriam Arévalo-Herrera; Liliana Soto; Blanca Liliana Perlaza; Nora Céspedes; Omaira Vera; Ana Milena Lenis; Anilza Bonelo; Giampietro Corradin; Sócrates Herrera
Journal:  Am J Trop Med Hyg       Date:  2011-02       Impact factor: 2.345

Review 5.  Hepatic phase of malaria: a crucial role as "go-between" with other stages.

Authors:  D Mazier; J Goma; S Pied; L Renia; A Nussler; F Miltgen; D Mattei; G Grau
Journal:  Bull World Health Organ       Date:  1990       Impact factor: 9.408

6.  Gamma interferon controls Eimeria vermiformis primary infection in BALB/c mice.

Authors:  M E Rose; D Wakelin; P Hesketh
Journal:  Infect Immun       Date:  1989-05       Impact factor: 3.441

7.  In vitro activity of CD4+ and CD8+ T lymphocytes from mice immunized with a synthetic malaria peptide.

Authors:  L Rénia; M S Marussig; D Grillot; S Pied; G Corradin; F Miltgen; G Del Giudice; D Mazier
Journal:  Proc Natl Acad Sci U S A       Date:  1991-09-15       Impact factor: 11.205

8.  Tomatine adjuvantation of protective immunity to a major pre-erythrocytic vaccine candidate of malaria is mediated via CD8+ T cell release of IFN-gamma.

Authors:  Karen G Heal; Andrew W Taylor-Robinson
Journal:  J Biomed Biotechnol       Date:  2010-03-11

Review 9.  [Malaria--biological aspects of an infectious disease of importance to humans].

Authors:  J P Hildebrandt
Journal:  Naturwissenschaften       Date:  1996-08

10.  Characterization of Plasmodium falciparum sporozoite surface protein 2.

Authors:  W O Rogers; A Malik; S Mellouk; K Nakamura; M D Rogers; A Szarfman; D M Gordon; A K Nussler; M Aikawa; S L Hoffman
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.